Treatment Patterns and Outcomes for Patients with Adrenocortical Carcinoma Associated with Hospital Case Volume in the United States

Annals of Surgical Oncology

Volumn 21, Issue 11, 2014, Pages 3509-3514

  Gratian, Lauren ^a   Pura, John ^a   Dinan, Michaela ^b   Reed, Shelby ^b   Scheri, Randall ^a   Roman, Sanziana ^a   Sosa, Julie Ann ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOTANE;

ADRENAL CORTEX CARCINOMA; ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CANCER THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEALTH CARE DISPARITY; HIGH VOLUME HOSPITAL; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; LOW VOLUME HOSPITAL; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RADICAL RESECTION; SURGICAL MORTALITY; SURVIVAL TIME; UNITED STATES; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; CANCER STAGING; CLINICAL PRACTICE; ELECTIVE SURGERY; FACTUAL DATABASE; FOLLOW UP; MIDDLE AGED; MORTALITY; PATHOLOGY; REGISTER; REOPERATION; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TREATMENT OUTCOME; WORKLOAD;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; DATABASES, FACTUAL; ELECTIVE SURGICAL PROCEDURES; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, HIGH-VOLUME; HOSPITALS, LOW-VOLUME; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NEOPLASM STAGING; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PHYSICIAN'S PRACTICE PATTERNS; REGISTRIES; REOPERATION; SURVIVAL RATE; WORKLOAD;

EID: 84932090460     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3931-z     Document Type: Article

References (23)

1. Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009;115:243–50.
2. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery. 1992;112:963–70.
3. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999;6:719–26.
4. Bellantone R, Ferrante A, Boscherini M, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery. 1997;122:1212–8.
5. Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001;25:891–7.
6. Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol. 2002;20:941–50.
7. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372–80.
8. Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189–97.
9. Berruti A, Fassnacht M, Baudin E, et al. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol. 2010;28:e401–2.
10. Neuroendocrine tumors. NCCN clinical practice guidelines in oncology, Version 1; 2012. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.
11. Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113:3130–6.
12. Kendrick ML, Lloyd R, Erickson L, et al. Adrenocortical carcinoma: surgical progress or status quo? Arch Surg. 2001;136:543–9.
13. Grubbs EG, Callender GG, Xing Y, et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol. 2010;17:263–70.
14. Vassiolopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma: clinical outcome at the end of the 20th century. Cancer. 2001;92:1113–21.
15. Winchester DP, Stewart AK, Bura C, Jones RS. The National Cancer Data Base: a clinical surveillance and quality improvement tool. J Surg Oncol. 2004;85:1–3.
16. Raghunathan TW, Lepkowksi JM, Van Hoewyk J, Solenbeger P. A multivariate technique for multiply imputing missing values using a sequence of regression models. Surv Method. 2001;27:85–95.
17. White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med. 2009;28:1982–98.
18. Park HS, Roman SA, Sosa JA. Outcomes from 3144 adrenalectomies in the United States. Which matters more, surgeon volume or specialty? Arch Surg. 2009;144:1060–7.
19. Villar JM, Moreno P, Ortega J, et al. Results of adrenal surgery. Data of a Spanish national survey. Langenbecks Arch Surg. 2010;395:837–43.
20. Kerkhofs TM, Verhoeven RH, Bonjer HJ, et al. Surgery for adrenocortical carcinoma in the Netherlands: analysis of the national cancer registry data. Eur J Endocrinol. 2013;169:83–9.
21. Lombardi CP, Raffaelli M, Boniardi M, et al. Adrenocortical carcinoma: effect of hospital volume on patient outcome. Langenbecks Arch Surg. 2012;397:201.
22. Fassnacht M, Johanssen S, Fenske W, et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab. 2010;95:4925–32.
23. Else T, Williams AR, Sabolch A, Jolly S, Miller BS, Hammer GD. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2014;99:455–61.